Clinical trials: Enoxaparin
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Thromboprophylaxis in Hospitalized Obese Patients
Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin
Venous thromboembolism (VTE), deep vein thrombosis (DVT) or pulmonary embolism (PE) is a common medical condition encountered during hospitalization in a medical environment.
- Trial name
- ITOHENOX (NCT01707732)
- Testing
- Enoxaparin
- Where
- France
- Volunteers
- 92 people
- Sponsor
- University Hospital, Rouen
Gastric Cancer, Gastroesophageal Cancer
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in…
- Trial name
- GASTRANOX (NCT00718354)
- Testing
- Enoxaparin, Standard Chemotherapy
- Where
- 15 sites in India
- Volunteers
- 740 people
- Sponsor
- Thrombosis Research Institute
Traumatic Intracranial Haemorrhage
OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study
Victims of trauma with severe head injury who have bled into their brains are at high risk of developing blood clots in their legs.
- Trial name
- OPTTICH (NCT02260908)
- Testing
- Enoxaparin
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McMaster University
Morbid Obesity, Pulmonary Embolism
Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome.
- Trial name
- NCT02128178
- Testing
- Enoxaparin 40 mg 2 hours before arm, Enoxaparin 40 mg 12 hours before arm
- Where
- Egypt
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Alive and Viable Births
Prevention of Unexplained Recurrent Abortion by Enoxaparine
Standard investigations fail to reveal any apparent cause in 50% of the cases of recurrent spontaneous abortion. Prothrombotic mechanisms were initially evoked.
- Trial name
- PREFIX (NCT00740545)
- Testing
- enoxaparine 40 mg daily
- Where
- 7 sites in France
- Volunteers
- 258 people
- Sponsor
- University Hospital, Brest
Osteoarthritis, Hip, Femur Head Necrosis
Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.
- Conditions
- Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures
- Trial name
- NCT02379663
- Testing
- Rivaroxaban, Enoxaparin, Normal saline
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Post Polypectomy Bleeding in Anticoagulated Patients, Gastrointestinal Hemorrhage
Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients
One of the well-known of complications post colonic polypectomy is bleeding usually occuring in the 2-week period following the procedure. Patients treated with oral anticoagulation (e.g.
- Trial name
- NCT02375646
- Testing
- Warfarin, LMW Heparin
- Volunteers
- 286 people
- Sponsor
- Hadassah Medical Organization
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- RECORD 2 (NCT00332020)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 126 sites in United States, Australia and 21 more
- Volunteers
- 2,457 people
- Sponsor
- Bayer
Pancreatic Cancer
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the experimental arm.
- Trial name
- PROSPECT (NCT00785421)
- Testing
- enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy
- Where
- Germany
- Volunteers
- 312 people
- Sponsor
- CONKO-Studiengruppe
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer
Thromboembolism, Prevention
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but…
- Trial name
- ODiXaHip (NCT00839826)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Austria, Belgium and 9 more
- Volunteers
- 641 people
- Sponsor
- Bayer
Venous Thromboembolism, Neoplasms
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Background Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this…
- Trial name
- Longheva (NCT01164046)
- Testing
- low molecular weight heparin, vitamin K antagonists
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- University Medical Center Groningen
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Venous Thromboembolism
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess different doses of a new drug (BAY 59-7939), taken as a tablet, are safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- ODIXaHIP-OD (NCT00396786)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 62 sites in Austria, Belgium and 11 more
- Volunteers
- 877 people
- Sponsor
- Bayer
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Pregnancy, Heart; Complications, Valve, Prosthesis
Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves
Pregnancy is associated with increased risk of thrombosis among women with mechanical prosthetic heart valves.However, the best anticoagulant treatment strategies for pregnant patients with prosthetic heart valves have been…
- Trial name
- NCT02240927
- Testing
- Low Molecular Weight Heparine : Enoxaparine, Enoxaparine and 2.5 mg Warfarin, Enoxaparine and 4mg Warfarin
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital